Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
RESEARCH TOOLSreports
Holding CNTX?
Track your performance easily
CNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $2.75
Previous Close$1.63
Volume280.05K
Average Volume (3M)257.87K
Market Cap
$108.56M
Enterprise Value$39.19M
Total Cash (Recent Filing)$84.80M
Total Debt (Recent Filing)$244.36K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 19, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,998,312
10 Day Avg. Volume175,012
30 Day Avg. Volume257,866
Standard Deviation0.33
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio24.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$6.50Price Target Upside354.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Context Therapeutics News
PremiumCompany Announcements
Context Therapeutics Acquires Rights to Innovate Cancer Antibodies
PremiumCompany Announcements
Context Therapeutics Bolsters Board with Industry Veterans
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.77 and its highest was $2.75 in the past 12 months.
What is Context Therapeutics’s market cap?
Currently, no data Available
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 118 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.13.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 74,998,314 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -5.856%.
Which hedge fund is a major shareholder of Context Therapeutics?
Among the largest hedge funds holding Context Therapeutics’s share is Blackstone Inc.. It holds Context Therapeutics’s shares valued at 5M.
---
Context Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (354.55% Upside)
$6.50 (354.55% Upside)
Hedge Fund Trend
Decreased
By 295.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.58%
12-Months-Change
Fundamentals
Return on Equity
-58.98%
Trailing 12-Months
Asset Growth
275.53%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
---
CNTX Stock 12 Month Forecast
Average Price Target
$6.50
▲(354.55% Upside)
Technical Analysis
Oncternal Therapeutics
―
Iterum Therapeutics
―
TRACON Pharmaceuticals
―
Kazia Therapeutics
―
Best Analysts Covering CNTX
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+25.70%
reiterated a buy rating 15 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +25.70% per trade.
---